Neos Therapeutics Inc  

(Public, NASDAQ:NEOS)   Watch this stock  
Find more results for Neos Therapeutics, Inc.�
+0.22 (1.38%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.82 - 16.40
52 week 11.53 - 28.99
Open 16.06
Vol / Avg. 37,250.00/98,459.00
Mkt cap 254.60M
P/E     -
Div/yield     -
EPS -2.01
Shares 15.94M
Beta     -
Inst. own 39%
Nov 11, 2015
Q3 2015 Neos Therapeutics Inc Earnings Call
Nov 10, 2015
Q3 2015 Neos Therapeutics Inc Earnings Release
Sep 3, 2015
Q2 2015 Neos Therapeutics Inc Earnings Call - Webcast
Sep 3, 2015
Q2 2015 Neos Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -4238.91% -2750.53%
Operating margin -3156.11% -2436.94%
EBITD margin - -2079.02%
Return on average assets -40.19% -47.87%
Return on average equity - -
CDP Score - -


2940 N State Highway 360 Ste 400
GRAND PRAIRIE, TX 75050-6424
United States - Map
+1-972-4081360 (Phone)
+1-972-4081143 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Neos Therapeutics, Inc. is a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD, and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.

Officers and directors

Alan Heller Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Vipin K. Garg Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Richard Eisenstadt Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Mark Tengler Chief Technology Officer
Age: 47
Bio & Compensation  - Reuters
Dorothy Engelking Vice President of Regulatory Affairs
Age: 54
Bio & Compensation  - Reuters
Thomas P McDonnell Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Beth P. Hecht Director
Bio & Compensation  - Reuters
Paul R. Edick Non-Executive Director
Age: 60
Bio & Compensation  - Reuters
Bryant E. Fong Non-Executive Director
Bio & Compensation  - Reuters
Gregory J. Robitaille Non-Executive Director
Bio & Compensation  - Reuters